Posted on January 4, 2019 by Sitemaster
Not so long ago, one of the new immunotherapeutic agents (a PD-1 inhibitor called pembrolizumab or Keytruda) was approved by the US Food and Drug Administration (FDA) for the treatment of so-called microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors — regardless of the biological site of origin of those tumors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: dMMR, genotype, Management, MSI-H, phenotype, prevalence, rare, risk | 1 Comment »
Posted on November 1, 2018 by Sitemaster
We have probably all heard terms like “liquid biopsy” and “genetic screening” and “cell-free” DNA analysis over the past few years. These are all terms related to the use of genetic and genomic information to “personalize” cancer diagnosis and its management. And they are potentially a huge big deal. But, … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: analysis, cancer, detection, DNA, Management, monitoring, risk | 4 Comments »
Posted on September 18, 2018 by Sitemaster
A new and potentially controversial article in Urology (the “Gold Journal”) has just suggested that regular, mass, population-based screening of men for risk of prostate cancer every 12 to 18 months remains a good idea. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Management, PSA, risk, screening, testing | 9 Comments »
Posted on September 17, 2018 by Sitemaster
A newly published article in JAMA Oncology has reported hypothetical costs savings to Medicare of $320 million over a 3-year time frame if men of > 70 years with low-risk prostate cancer are simply “observed” as opposed being given immediate treated. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: conservative, cost, Management, Medicare, observation, saving | Leave a comment »
Posted on August 20, 2018 by Sitemaster
For those who are interested in this evolving topic, we recommend listening to Dr. Charles Ryan’s 16-minute-long discussion with Heather Cheng, MD, PhD, entitled “Genetic evaluation and counseling in prostate cancer treatment”. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, genetics, genomics, Management, PARP, risk | 3 Comments »
Posted on August 2, 2018 by Sitemaster
One of our regular correspondents (who lives in England) was recently told something rather interesting by the Consultant Urologist he sees in the UK. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: change, future, Management, past, progress, Treatment | 4 Comments »
Posted on August 1, 2018 by Sitemaster
Your sitemaster has long argued that it is perfectly reasonable for many younger men diagnosed with low- and very low-risk forms of prostate cancer to be managed initially on active surveillance (despite reticence on the parts of many physicians and many patients). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, age, AS, Diagnosis, Management, surveillance | 2 Comments »